Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) Enterprise Value (EV): $62.97B

The enterprise value (EV) for Zoetis Inc. (ZTS) is $62.97B as of Tuesday, June 9, 2026.

ZTS Enterprise Value (EV) Metrics

ENTERPRISE VALUE (EV)

$62.97B

ZTS Competitors' Enterprise Value (EV)

NAMEMARKET CAPENTERPRISE VALUE (EV)
Zoetis Inc. (ZTS)$62.97B
Centene Corporation (CNC)$31.94B$21.10B
IQVIA Holdings Inc. (IQV)$31.09B$52.94B
Agilent Technologies, Inc. (A)$38.26B$42.98B
DexCom, Inc. (DXCM)$30.17B$26.37B
Biogen Inc. (BIIB)$29.00B$29.76B
Veeva Systems Inc. (VEEV)$27.37B$32.05B
Humana Inc. (HUM)$43.60B$39.59B
Waters Corporation (WAT)$24.19B$23.51B
Mettler-Toledo International Inc. (MTD)$23.50B$31.01B

Enterprise Value Calculation

Market Cap

$34.46B

+

Total Debt

$9.29B

Cash

$2.31B

=

Enterprise Value

$62.97B

EV-Based Valuation Multiples

Why use EV instead of Market Cap?

  • EV accounts for debt - an acquirer must pay or assume it
  • EV deducts cash - the acquirer effectively receives it
  • EV enables fair comparison of companies with different capital structures
  • EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral

Zoetis Inc. Enterprise Value (EV) Formula & Definition

Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Zoetis Inc. Enterprise Value (EV) FAQ

What is the enterprise value (EV) for Zoetis Inc. (ZTS)?
The enterprise value (EV) for ZTS stock is $62.97B.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck